Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Hummingbird Bioscience
At a recent forum in Seoul, SK Group unveiled its biotech investment strategy and noted the next few years could present multiple major opportunities for Korean biotechs.
BioMed X teams with J&J on inflammation, drug delivery research. Stem cell firm Calidi inks licensing deals with U. of Chicago, City of Hope and Northwestern. MD Anderson teams with Blueprint and Hummingbird.
To bolster its life sciences and diagnostics portfolios, Novo Holdings has made another major investment to acquire BBI Group.
Private Company Edition: More $100m-plus mega-rounds means another billion-dollar week for venture capital deals, including financings for G2 Bio, Hummingbird and Numab. Also, BioTheryX brings in $92m, Vedere launches with $77m and Eliem raises $60m two months after launching with $80m.
- Large Molecule
Drug Discovery Tools